Al-Saffar Anas Kh, Meijer Carl Hampus, Gannavarapu Venkata Ram, Hall Gustav, Li Yichen, Diaz Tartera Hetzel O, Lördal Mikael, Ljung Tryggve, Hellström Per M, Webb Dominic-Luc
Department of Medical Sciences, Gastroenterology and Hepatology Unit, Uppsala University, Uppsala, Sweden.
Department of Medicine, Division of Gastroenterology and Hepatology, Danderyds Sjukhus, Danderyd, Sweden.
Gastroenterol Res Pract. 2017;2017:1745918. doi: 10.1155/2017/1745918. Epub 2017 Oct 23.
Intestinal fatty acid binding protein (I-FABP) indicates barrier integrity.
determine if I-FABP is elevated in active Crohn's disease (CD) and if I-FABP parallels anti-TNF antibody (infliximab) induced lowering of TNF and Harvey-Bradshaw Index (HBI) as potential indicator of mucosal healing. I-FABP distribution along human gut was determined. Serum from 10 CD patients collected during first three consecutive infliximab treatments with matched pretreatment and follow-up samples one week after each treatment and corresponding HBI data were analyzed. I-FABP reference interval was established from 31 healthy subjects with normal gut permeability. I-FABP and TNF were measured by ELISA; CRP was measured by nephelometry. Healthy tissue was used for I-FABP immunohistochemistry. Pretreatment CD patient TNF was 1.6-fold higher than in-house reference interval, while I-FABP was 2.5-fold higher, which lowered at follow-ups. Combining all 30 infusion/follow-up pairs also revealed changes in I-FABP. HBI followed this pattern; CRP declined gradually. I-FABP was expressed in epithelium of stomach, jejunum, ileum, and colon, with the highest expression in jejunum and ileum. I-FABP is elevated in active CD with a magnitude comparable to TNF. Parallel infliximab effects on TNF, HBI, and I-FABP were found. I-FABP may be useful as an intestine selective prognostic marker in CD.
肠脂肪酸结合蛋白（I-FABP）表明屏障完整性。
确定I-FABP在活动期克罗恩病（CD）中是否升高，以及I-FABP是否与抗TNF抗体（英夫利昔单抗）诱导的TNF降低和哈维-布拉德肖指数（HBI）平行，作为黏膜愈合的潜在指标。确定了I-FABP在人肠道中的分布。分析了10例CD患者在连续三次英夫利昔单抗治疗期间收集的血清，每次治疗前和治疗后一周的匹配预处理和随访样本以及相应的HBI数据。从31名肠道通透性正常的健康受试者中建立了I-FABP参考区间。通过ELISA测量I-FABP和TNF；通过比浊法测量CRP。使用健康组织进行I-FABP免疫组织化学。CD患者治疗前的TNF比内部参考区间高1.6倍，而I-FABP高2.5倍，随访时降低。合并所有30对输注/随访数据也显示了I-FABP的变化。HBI遵循这种模式；CRP逐渐下降。I-FABP在胃、空肠、回肠和结肠的上皮中表达，在空肠和回肠中表达最高。活动期CD中I-FABP升高，幅度与TNF相当。发现英夫利昔单抗对TNF、HBI和I-FABP有平行作用。I-FABP可能作为CD中肠道选择性预后标志物有用。
